Guard Therapeutics International Future Growth
Future criteria checks 1/6
Guard Therapeutics International's earnings are forecast to decline at 9% per annum while its annual revenue is expected to grow at 149% per year. EPS is expected to grow by 97.8% per annum. Return on equity is forecast to be 147.9% in 3 years.
Key information
-9.0%
Earnings growth rate
97.8%
EPS growth rate
Biotechs earnings growth | 35.7% |
Revenue growth rate | 149.0% |
Future return on equity | 147.9% |
Analyst coverage | Low |
Last updated | 23 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 299 | N/A | N/A | N/A | 1 |
12/31/2025 | N/A | -91 | -91 | -91 | 1 |
12/31/2024 | N/A | -86 | -101 | -101 | 1 |
6/30/2024 | N/A | -79 | -81 | -81 | N/A |
3/31/2024 | N/A | -88 | -101 | -101 | N/A |
12/31/2023 | N/A | -113 | -116 | -116 | N/A |
9/30/2023 | N/A | -137 | -133 | -133 | N/A |
6/30/2023 | N/A | -146 | -138 | -138 | N/A |
3/31/2023 | N/A | -134 | -120 | -120 | N/A |
12/31/2022 | N/A | -113 | -102 | -102 | N/A |
9/30/2022 | N/A | -95 | -93 | -93 | N/A |
6/30/2022 | N/A | -97 | -93 | -93 | N/A |
3/31/2022 | N/A | -88 | -86 | -86 | N/A |
12/31/2021 | N/A | -82 | -78 | -78 | N/A |
9/30/2021 | N/A | -69 | -63 | -63 | N/A |
6/30/2021 | N/A | -47 | -43 | -43 | N/A |
3/31/2021 | N/A | -44 | -40 | -40 | N/A |
12/31/2020 | N/A | -40 | -38 | -38 | N/A |
9/30/2020 | N/A | -43 | -36 | -37 | N/A |
6/30/2020 | N/A | -39 | -38 | -38 | N/A |
3/31/2020 | N/A | -41 | -39 | -39 | N/A |
12/31/2019 | N/A | -45 | -60 | -60 | N/A |
9/30/2019 | N/A | -73 | -65 | -66 | N/A |
6/30/2019 | N/A | -82 | -65 | -66 | N/A |
3/31/2019 | N/A | -86 | -78 | -78 | N/A |
12/31/2018 | N/A | -87 | -58 | -58 | N/A |
9/30/2018 | N/A | -61 | -59 | -58 | N/A |
6/30/2018 | N/A | -63 | -61 | -59 | N/A |
3/31/2018 | N/A | -67 | N/A | -70 | N/A |
12/31/2017 | N/A | -68 | N/A | -66 | N/A |
9/30/2017 | N/A | -72 | N/A | -72 | N/A |
6/30/2017 | N/A | -68 | N/A | -68 | N/A |
3/31/2017 | N/A | -61 | N/A | -43 | N/A |
12/31/2016 | N/A | -52 | N/A | -47 | N/A |
9/30/2016 | N/A | -43 | N/A | -35 | N/A |
6/30/2016 | N/A | -35 | N/A | -34 | N/A |
3/31/2016 | N/A | -32 | N/A | -35 | N/A |
12/31/2015 | N/A | -30 | N/A | -27 | N/A |
9/30/2015 | N/A | -23 | N/A | -24 | N/A |
6/30/2015 | 0 | -20 | N/A | -18 | N/A |
3/31/2015 | 0 | -15 | N/A | -14 | N/A |
12/31/2014 | 0 | -14 | N/A | -15 | N/A |
9/30/2014 | 2 | -12 | N/A | -10 | N/A |
6/30/2014 | 5 | -9 | N/A | -8 | N/A |
3/31/2014 | 7 | -7 | N/A | -4 | N/A |
12/31/2013 | 8 | -5 | N/A | -3 | N/A |
9/30/2013 | 8 | -4 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 5LH0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 5LH0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 5LH0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 5LH0 is forecast to have no revenue next year.
High Growth Revenue: 5LH0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 5LH0's Return on Equity is forecast to be very high in 3 years time (147.9%).